APP to help fill any heparin shortage

SCHAUMBURG -- APP Pharmaceuticals Inc. said Tuesday that, in response to FDA and hospital concerns about a potential shortage of heparin, it will immediately increase manufacturing of its multi-dose vials of this blood thinner. APP said it acquires its active ingredient, heparin USP, from multiple manufacturers that have been inspected and approved by the FDA, including its supplier from China.